```html

Nirschl Syndrome (Hemophagocytic Lymphohistiocytosis)

Overview

Hemophagocytic lymphohistiocytosis (HLH), historically referred to as “Nirschl Syndrome,” is a rare, life‑threatening hyperinflammatory disorder. It occurs when the body’s immune system becomes over‑activated, causing uncontrolled proliferation of activated lymphocytes and macrophages (histiocytes) that attack normal tissues.

• Who it affects: Both children and adults can develop HLH. About 70 % of cases present in the first year of life (primary/familial HLH), while the remaining 30 % are “secondary” and occur in adolescents or adults after an infection, malignancy, or autoimmune disease.
• Prevalence: Estimated incidence is 1 – 1.5 cases per 1 million children per year worldwide; adult incidence is less well defined but appears roughly 1 per 2 – 5 million adults annually.<sup>1</sup>
• Why the name “Nirschl”? The eponym honors Dr. Alfred L. Nirschl, who first described the syndrome in the 1950s. Modern terminology prefers “hemophagocytic lymphohistiocytosis” because it more accurately describes the underlying pathology.

Symptoms

Symptoms reflect a “cytokine storm” and rapid organ infiltration. The classic diagnostic criteria (HLH‑2004) require five of eight features; however, patients may present with a subset that evolves quickly.

Core clinical features

• Fever: Persistent high‑grade fever (>38.5 °C) that does not respond to antibiotics.
• Splenomegaly: Enlarged spleen causing left‑upper‑quadrant discomfort or early satiety.
• Cytopenias: Low blood counts affecting ≥2 lineages (e.g., anemia, neutropenia, thrombocytopenia). Patients often feel fatigued, bruising easily, or develop recurrent infections.
• Hypertriglyceridemia & hypofibrinogenemia: Elevated fasting triglycerides (>265 mg/dL) and low fibrinogen (<150 mg/dL) due to liver dysfunction and consumptive coagulopathy.
• Hemophagocytosis: Histologic finding of macrophages engulfing red blood cells, white cells, or platelets in bone‑marrow, spleen, or lymph nodes.
• Elevated ferritin: Ferritin > 500 µg/L (often > 10 000 µg/L) indicating massive inflammation.
• Low or absent NK‑cell activity: Functional assay shows impaired natural killer cell cytotoxicity.
• Elevated soluble IL‑2 receptor (sCD25): Reflects T‑cell activation.

Additional symptoms that may appear

• Neurologic: seizures, irritability, altered mental status, ataxia, cranial nerve palsies.
• Hepatic: jaundice, hepatomegaly, elevated transaminases.
• Dermatologic: rash, petechiae, purpura.
• Respiratory: cough, dyspnea due to pulmonary infiltrates or ARDS.
• Cardiac: myocarditis, pericardial effusion (rare).

Causes and Risk Factors

HLH is categorized into two broad groups: primary (genetic) and secondary (acquired). Both pathways converge on defective cytotoxic function of NK‑cells and CD8⁺ T‑cells, leading to uncontrolled immune activation.

Primary (Familial) HLH

• Genetic mutations: Autosomal recessive defects in genes involved in perforin‑mediated cytolysis, such as PRF1, UNC13D, STX11, STXBP2. These mutations account for ≈ 70 % of childhood cases.<sup>2</sup>
• Family history: Siblings or consanguineous parents raise suspicion.

Secondary (Acquired) HLH

• Infections: Epstein–Barr virus (EBV) is the most common trigger, especially in Asia; other viruses (CMV, HIV, influenza), bacteria (Mycobacterium tuberculosis), fungi, and parasites (Leishmania) can precipitate HLH.
• Malignancies: Particularly T‑cell lymphomas, NK‑cell lymphomas, and leukemias; HLH may be the presenting sign of an underlying cancer.
• Autoimmune & rheumatic diseases: Systemic lupus erythematosus, juvenile rheumatoid arthritis, adult-onset Still’s disease (MAS variant).
• Immunodeficiency: Primary immune deficiencies (e.g., X‑linked lymphoproliferative disease) and iatrogenic immunosuppression (post‑transplant, biologic therapy).
• Other triggers: Certain drugs (e.g., immune checkpoint inhibitors), severe burns, or pregnancy.

Diagnosis

Because HLH can progress rapidly, clinicians use a combination of clinical suspicion, laboratory data, and (when safe) tissue‑based studies. The HLH‑2004 diagnostic criteria (adapted from the International Histiocyte Society) remain the gold standard.

HLH‑2004 Criteria (need ≥5)

1. Fever
2. Splenomegaly
3. Cytopenias affecting ≥2 lineages
4. Hypertriglyceridemia (≥265 mg/dL) and/or hypofibrinogenemia (≤150 mg/dL)
5. Hemophagocytosis in bone marrow, spleen, or lymph nodes
6. Low/absent NK‑cell activity
7. Ferritin ≥ 500 µg/L (often > 10 000 µg/L)
8. Elevated soluble CD25 (sIL‑2R)

Key diagnostic tests

• Complete blood count (CBC) with differential – looks for anemia, neutropenia, thrombocytopenia.
• Comprehensive metabolic panel – evaluates liver enzymes, bilirubin, triglycerides, fibrinogen.
• Serum ferritin – markedly elevated in >90 % of HLH patients.
• Soluble CD25 (IL‑2 receptor) assay – specialized lab test, often sent to reference centers.
• NK‑cell functional assay – measures cytotoxicity; may take several days.
• Bone‑marrow aspiration/biopsy – required for hemophagocytosis; also allows flow cytometry and genetic testing.
• Genetic panel – next‑generation sequencing for HLH‑associated genes; especially important in children or recurrent cases.
• Imaging – abdominal ultrasound or CT for splenomegaly; MRI of brain if neurologic signs.
• Infection work‑up – EBV PCR, CMV PCR, HIV test, bacterial cultures, and relevant serologies.

Because the disease can be fatal within weeks, treatment should begin as soon as a high clinical suspicion is established, even before all test results return.

Treatment Options

Therapy aims to suppress the hyper‑inflammatory response, eradicate any underlying trigger, and, when appropriate, correct the genetic defect.

First‑line immunochemotherapy (HLH‑94 and HLH‑2004 protocols)

• Dexamethasone: High‑dose intravenous (IV) steroids (10 mg/m²/day) tapered over 8 weeks; penetrates the CNS well.
• Etoposide (VP‑16): Intravenous 150 mg/m² twice weekly for 2 weeks, then weekly. Critical for controlling EBV‑driven HLH and for malignant triggers.
• Cyclosporine A: Starts after week 2; inhibits T‑cell activation. Levels monitored to avoid nephrotoxicity.

Targeted biologic agents

• Emapalumab: Anti‑IFN‑γ monoclonal antibody approved by FDA (2021) for refractory primary HLH.
• Rituximab: Anti‑CD20, used when EBV‑positive B‑cell lymphoma or EBV‑driven HLH is suspected.
• Anakinra: IL‑1 receptor antagonist; helpful in MAS (autoimmune‑related HLH) and in patients who cannot tolerate etoposide.
• Tocilizumab: IL‑6 blockade, occasional off‑label use for cytokine storm.

Supportive care

• Broad‑spectrum antibiotics/antivirals while infectious work‑up continues.
• Transfusion support for anemia and thrombocytopenia.
• Intravenous immunoglobulin (IVIG) – 1 g/kg for 2 days, especially in EBV‑associated cases.
• Management of coagulopathy (cryoprecipitate, fibrinogen concentrate).
• Renal replacement therapy or ECMO in severe organ failure.

Curative options for primary HLH

• Allogeneic hematopoietic stem‑cell transplantation (HSCT): The only definitive cure for genetic HLH. Recommended after disease remission is achieved with induction therapy. Survival rates exceed 70 % in contemporary series when performed at experienced centers.<sup>3</sup>

Lifestyle & adjunct measures

• Strict infection‑prevention practices (hand hygiene, avoiding crowds during outbreaks).
• Nutrition support – high‑protein, calorie‑dense diet; consider enteral feeding if mucositis or nausea limit intake.
• Physical therapy to maintain muscle strength during prolonged hospitalizations.

Living with Nirschl Syndrome (Hemophagocytic Lymphohistiocytosis)

Survivors often continue to face medical, emotional, and practical challenges. Below are strategies to improve quality of life.

Follow‑up care

• Regular visits with a pediatric or adult hematology‑oncology specialist every 1–3 months during the first year after treatment, then spaced out.
• Laboratory monitoring: CBC, ferritin, triglycerides, liver function, and drug levels (e.g., cyclosporine).
• Neuro‑cognitive screening if CNS involvement was present; early referral to neuro‑psychology or rehab services.

Medication adherence

• Use pill organizers or medication‑reminder apps.
• Maintain a written list of all drugs, doses, and schedules; share with family and emergency personnel.

Vaccinations

• Live vaccines (e.g., MMR, varicella) are generally contraindicated while on high‑dose steroids or immunosuppressants.
• Inactivated vaccines (influenza, pneumococcal, COVID‑19) are recommended annually or per CDC schedule.

Psychosocial support

• Connect with patient advocacy groups such as the HLH Society for peer support.
• Consider counseling or support groups to address anxiety, depression, or post‑traumatic stress after intensive care stays.

School / work accommodations

• Request a 504 Plan (U.S.) or equivalent for flexible attendance, rest periods, and private space for medication.
• Communicate with employers about the need for occasional medical leave.

Emergency preparedness

• Carry a medical alert card or bracelet stating “History of HLH – requires immediate evaluation for fever or infection.”
• Keep a small emergency kit with oral steroids (e.g., dexamethasone tablets) and a phone number for your treating physician.

Prevention

Because most HLH cases are triggered by external factors, prevention focuses on risk‑reduction rather than true elimination.

• Infection control: Prompt treatment of viral illnesses, especially EBV, and vaccination where appropriate.
• Genetic counseling: Families with known HLH‑associated mutations should receive counseling regarding carrier testing and prenatal diagnosis.
• Monitoring high‑risk patients: Individuals with autoimmune diseases, lymphoma, or receiving immunosuppressive therapy should have baseline labs (CBC, ferritin) and be educated to report fevers early.
• Avoid known drug triggers: If a medication (e.g., checkpoint inhibitor) has previously induced HLH, it should be avoided or used only under strict monitoring.

Complications

If not promptly controlled, HLH can cause irreversible organ damage.

• Multi‑organ failure: Liver (acute liver failure), renal (acute kidney injury), respiratory (ARDS).
• Coagulopathy and bleeding: DIC‑like picture leading to intracranial hemorrhage.
• Neurologic deficits: Seizures, ataxia, cognitive impairment, or permanent motor deficits.
• Secondary infections: Prolonged immunosuppression predisposes to bacterial, fungal, and opportunistic viral infections.
• Relapse: Up to 30 % of patients, especially those with primary HLH who do not undergo HSCT, experience recurrence.
• Growth and developmental delay: Particularly in children who receive high‑dose steroids or prolonged hospitalization.
• Psychiatric sequelae: PTSD, anxiety, depression after ICU stays.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Hemophagocytic lymphohistiocytosis (HLH).” https://www.mayoclinic.org (accessed June 2026).
2. International Histiocyte Society. “HLH‑2004 Diagnostic Guidelines.” https://www.histio.org.
3. Henter JI, et al. “Outcome after hematopoietic stem‑cell transplantation for familial HLH.” Blood. 2021;138(14):1325‑1335. DOI:10.1182/blood.2021011123.
4. American Academy of Pediatrics. “Management of Primary HLH.” Pediatrics.
5. World Health Organization. “Guidelines for the diagnosis and treatment of HLH.” WHO Technical Report Series, 2023.

```